Method for preventing or treating hearing impairment

By using compositions of phytol and fucoxanthin, the cochlea hair cells are protected, and the hearing loss caused by difficult prevention or treatment in the prior art is solved, and the hearing threshold and hair cells are reduced in the prior art. Functional protection improves the quality of life.

CN118922184APending Publication Date: 2024-11-08MACKAY MEDICAL COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380025511.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-04
Filing Date
2023-03-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent or treat sensory neurological hearing defects caused by noise exposure, drug use, etc., hearing aids cannot correct suprathreshold or postcochlear damage, and lack methods to protect hair cell functions.

Method used

Use phytol hexaphosphate or its salt and its derivatives and fucoxanthin or its derivatives as a composition for preventing or treating hearing defects, and administering or other means to protect cochlear hair cells and reduce hearing. Threshold, synergistically prevents or treats hearing loss.

Benefits of technology

Effectively improving hair cell loss, lowering hearing thresholds, and protecting cochlear function, it provides an alternative method to prevent or treat hearing loss, improving patients' quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922184A_ABST
    Figure CN118922184A_ABST
Patent Text Reader

Abstract

The present application provides a method for preventing or treating hearing impairment in a subject in need thereof, the method comprising administering to the subject an effective amount of phytic acid or a salt thereof or a derivative thereof, fucoxanthin or a derivative thereof, or a combination thereof. The present application also provides a composition for preventing or treating hearing impairment in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the prevention or treatment of hearing loss, in particular, a method for preventing or treating hearing loss by administering a composition to a subject in need thereof, the composition comprising phytate or a salt thereof or a derivative thereof, fucoxanthin or a derivative thereof, or a combination thereof. The present application also relates to a composition for preventing or treating hearing loss in a subject in need thereof. Background Art

[0002] One of the most common types of hearing loss is sensorineural hearing loss (SNHL) (also known as sensorineural deafness), which is caused by the loss of hair cells and / or auditory spiral ganglion neurons or their function, resulting in communication difficulties in a large proportion of this group of people. Hair cells are sensory cells in the cochlea that are responsible for converting sound into electrical signals. The human inner ear contains approximately 15,000 hair cells per cochlea at birth, and these cells do not regenerate after birth and can be lost due to various genetic or environmental factors, such as noise exposure, mechanical damage, toxicity from ototoxic drugs (e.g., cisplatin and aminoglycosides), viral infections (e.g., otitis media), aging, and genetic defects.

[0003] Hearing dysfunction in humans is often caused by aging or acute and chronic exposure to loud sounds or ototoxic chemicals. Sounds above 85 decibels can cause hearing loss, and the sounds are produced by sources such as gunshots, bomb explosions, jet engines, power tools, and concerts. Other common daily activities and products also produce high-intensity noise, such as the use of hair dryers, lawn mowers, and blenders. Side effects of noise-induced hearing loss include tinnitus, decreased speech comprehension, hyperacusis, loudness recruitment, and various types of auditory processing disorders. In addition, exposure to commonly used medications may also cause hearing dysfunction. For example, patients receiving chemotherapy, antibiotics, and other drug treatments often experience hearing loss as a side effect. In addition, hearing dysfunction is also a common result of aging.

[0004] Currently, few cases of hearing loss can be truly cured. Audiological devices such as hearing aids are primarily used to amplify sound and cannot correct suprathreshold or post-cochlear damage, so they have limitations, including the inability to improve speech intelligibility, tinnitus, hyperacusis, ringing, and various other types of central auditory processing disorders. On the other hand, for age-related, noise- or drug-induced auditory dysfunction, prevention is an effective way to "cure" the disease or reduce its severity, such as avoiding excessive noise and using ear protectors, practicing a healthy lifestyle, and avoiding exposure to ototoxic drugs and substances as much as possible.

[0005] Hair cells are also found in the utricle of the vestibule, an organ that regulates balance. Therefore, there remains an unmet need to protect or promote the function of hair cells before and after injury, thereby restoring hearing and vestibular function. Summary of the invention

[0006] In view of the foregoing, it was surprisingly found that inositol hexaphosphate (also known as phytic acid or IP6) can improve hair cell loss when administered, representing an alternative strategy for preventing or treating hearing loss. In addition, fucoxanthin was also found to protect cochlear hair cells and reduce hearing thresholds, and the combination of inositol hexaphosphate and fucoxanthin even has a synergistic effect in preventing or treating hearing loss.

[0007] In at least one embodiment of the present application, a composition for preventing or treating hearing loss is provided, the composition comprising at least one of phytate or its salt or derivative and fucoxanthin or its derivative, and at least one of its pharmaceutically acceptable excipient and its food excipient. In some embodiments, the composition may include a combination of phytate or its salt or derivative and fucoxanthin or its derivative.

[0008] In at least one embodiment of the present application, the salt or derivative of phytate is selected from the group consisting of sodium phytate, potassium phytate, calcium phytate, dipotassium phytate, calcium magnesium phytate, magnesium phytate and sodium phytate dodecahydrate.

[0009] In at least one embodiment of the present application, the derivative of fucoxanthin may be fucoxanthinol, iso-fucoxanthin, iso-fucoxanthinol or amarouciaxanthin A.

[0010] In at least one embodiment of the present application, phytate or its salt or derivative thereof and fucoxanthin or its derivative thereof are independently present in an amount of 0.1% to 60% by weight of the composition, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.75%, 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% and 60%. In some embodiments, the amount of phytate or its salt or derivative thereof or fucoxanthin or its derivative thereof in the composition has a lower limit selected from 0.1%, 0.5%, 1%, 5% and 10% by weight of the composition, and an upper limit selected from 60%, 50%, 40%, 30%, 25%, 20% and 15% by weight of the composition. In some embodiments, phytate or a salt thereof or a derivative thereof or fucoxanthin or a derivative thereof is present in an amount of 1% to 60% by weight of the composition.

[0011] In at least one embodiment of the present application, if the composition includes phytate or its salt or derivatives thereof and does not contain fucoxanthin or its derivatives, the phytate or its salt or derivatives thereof is used as the only active ingredient in the composition for preventing or treating hearing loss. In some embodiments, phytate or its salt or derivatives thereof may be combined with an additional active ingredient (e.g., an active ingredient other than fucoxanthin or its derivatives) for preventing or treating hearing loss.

[0012] In at least one embodiment of the present application, if the composition includes fucoxanthin or its derivatives and does not contain phytate or its salts or derivatives, the fucoxanthin or its derivatives is used as the only active ingredient in the composition for preventing or treating hearing loss. In some embodiments, fucoxanthin or its derivatives may be combined with additional active ingredients (e.g., active ingredients other than phytate or its salts or derivatives) for preventing or treating hearing loss.

[0013] In at least one embodiment of the present application, the composition includes a combination of phytate or its salt or derivative thereof and fucoxanthin or its derivative, and may or may not contain additional active ingredients for preventing or treating hearing loss.

[0014] In at least one embodiment of the present application, the composition provided herein may be a pharmaceutical composition or an edible composition. In some embodiments, the pharmaceutical composition of the present application includes phytate or its salt or derivative thereof, fucoxanthin or its derivative, or a combination thereof, and a pharmaceutically acceptable excipient thereof. In some embodiments, the edible composition of the present application includes phytate or its salt or derivative thereof, fucoxanthin or its derivative, or a combination thereof, and a food excipient thereof.

[0015] In at least one embodiment of the present application, the pharmaceutically acceptable excipient or the food excipient is selected from the group consisting of fillers, binders, preservatives, disintegrants, lubricants, suspending agents, wetting agents, solvents, surfactants, acids, flavoring agents, polyethylene glycol (PEG), alkyl glycols, sebacic acid, dimethyl sulfoxide, alcohols, calcium stearate, microcrystalline cellulose, silicon dioxide, gelatin, fat, glycerin, dietary fiber, alginate, pectin, carrageenan, amidated pectin, xanthan gum, gellan gum, karaya gum, rhamnose gum, welan gum, gum ghatti, gum arabic, and any combination thereof.

[0016] In at least one embodiment of the present application, the phytate or its salt or derivative thereof or the fucoxanthin or its derivative thereof in the composition may be synthesized or naturally occurring. In some embodiments, the phytate or its salt or derivative thereof may be naturally occurring in grains, such as soybeans, barley, corn, millet, rice bran, germ rice, wheat, buckwheat, fair groat, roasted groat, oak, and quinoa seeds. In some embodiments, fucoxanthin or its derivative may be naturally occurring in brown algae (e.g., Phaeophyceae, such as Undaria pinnatifida) and diatoms (e.g., Bacillariophyceae, such as Thalassiosira pseudonana).

[0017] In at least one embodiment of the present application, the composition provided herein may be an edible composition, which includes at least one of soybean, barley, corn, millet, rice bran, germ rice, wheat, buckwheat, husked grains, roasted husked grains, oak, quinoa seeds, seaweed and extracts thereof.

[0018] In at least one embodiment of the present application, the composition is in a form selected from the group consisting of injection, dry powder, lozenge, oral solution, tablet, film, buccal lozenge, capsule, granule, pill, gel, lotion, ointment, emulsion, paste, cream, eye drops and ointment.

[0019] In at least one embodiment of the present application, a method for preventing or treating hearing loss in a subject in need thereof is provided. In some embodiments, the method comprises administering to the subject an effective amount of the above composition. In some embodiments, the method comprises administering to the subject an effective amount of phytate or a salt thereof or a derivative thereof. In some embodiments, the method comprises administering to the subject an effective amount of fucoxanthin or a derivative thereof.

[0020] In at least one embodiment of the present application, phytate or its salt or derivative thereof and fucoxanthin or its derivative thereof are administered to the subject simultaneously or sequentially. In the case of sequential administration, phytate or its salt or derivative thereof may be administered to the subject first, and then fucoxanthin or its derivative thereof, or vice versa.

[0021] In at least one embodiment, the phytate or its salt or derivative thereof and fucoxanthin or its derivative thereof used in the present application can be formulated with one or more pharmaceutically acceptable excipients and / or one or more food excipients as needed. In some embodiments, the phytate or its salt or derivative thereof and fucoxanthin or its derivative thereof are formulated into a single formulation that can be administered to a subject simultaneously. In some embodiments, the first formulation (such as phytate or its salt or derivative thereof) and the second formulation (such as fucoxanthin or its derivative) are each formulated into a separate formulation that can be administered to a subject simultaneously or sequentially.

[0022] In at least one embodiment of the present application, phytate or its salt or derivative thereof and fucoxanthin or its derivative thereof are independently administered to a subject in an effective amount of about 1 mg / kg / day to about 500 mg / kg / day. In some embodiments, the effective amount of phytate or its salt or derivative thereof or fucoxanthin or its derivative administered to a subject has a lower limit selected from 1 mg / kg / day, 3 mg / kg / day, 5 mg / kg / day, 10 mg / kg / day, 15 mg / kg / day, 20 mg / kg / day and 30 mg / kg / day, and an upper limit selected from 500 mg / kg / day, 400 mg / kg / day, 300 mg / kg / day, 200 mg / kg / day, 100 mg / kg / day, 90 mg / kg / day, 80 mg / kg / day, 70 mg / kg / day, 60 mg / kg / day, 50 mg / kg / day and 40 mg / kg / day. In some embodiments, phytate or a salt thereof or a derivative thereof or fucoxanthin or a derivative thereof is administered to a subject in an effective amount of about 3 mg / kg / day to about 80 mg / kg / day.

[0023] In at least one embodiment of the present application, the hearing loss is congenital or acquired, such as hearing loss caused by at least one of infection, noise exposure, chemotherapy, antibiotics and aging.

[0024] In at least one embodiment of the present application, the subject suffers from hearing loss involving degeneration or loss of hair cells. In some embodiments, the hair cells may be vestibular hair cells, cochlear hair cells, or a combination thereof. In some embodiments, the subject suffers from sensorineural hearing loss, tinnitus, or vertigo. In some embodiments, the subject suffers from vertigo and concomitant sensorineural hearing loss. In some embodiments, the subject suffers from acute hearing loss, chronic hearing loss, primary tinnitus, Meniere's disease, or labyrinthine concussion.

[0025] In at least one embodiment of the present application, the composition can be administered to the subject orally, intravenously, subcutaneously, intradermally, intrathecally, intraperitoneally, intranasally, intramuscularly, intrapleurally, topically, or by aerosolization.

[0026] In at least one embodiment of the present application, a composition for preventing or treating hearing loss in a subject in need thereof is provided. In some embodiments, the composition comprises at least one of phytate or a salt thereof or a derivative thereof and fucoxanthin or a derivative thereof, and at least one of a pharmaceutically acceptable excipient thereof and a food excipient thereof.

[0027] In at least one embodiment of the present application, a composition is provided for use in preparing a medicament for preventing or treating hearing loss in a subject in need thereof. In some embodiments, the composition comprises at least one of phytate or a salt thereof or a derivative thereof and fucoxanthin or a derivative thereof, and at least one of a pharmaceutically acceptable excipient thereof and a food excipient thereof.

[0028] In some embodiments, the phytate or its salt or derivative thereof, fucoxanthin or its derivative, and combinations thereof provided herein can protect hair cells and increase hearing thresholds, and thus can be used to prevent or treat hearing loss (e.g., hearing loss caused by infection, noise exposure, chemotherapy, antibiotics, and aging), and improve the quality of life of patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The present application can be more fully understood by reading the following detailed description of embodiments and referring to the accompanying drawings.

[0030] Figures 1A to 1C Experimental designs for three animal models of hearing loss are shown. Figure 1ACisplatin-induced SNHL mice were shown, wherein IP6 (40 mg / kg or 80 mg / kg) was injected intraperitoneally (IP) into 2-month-old mice, and cisplatin (3 mg / kg) was injected intraperitoneally for 5 consecutive days 2 hours after IP6 administration to induce SNHL. One week later, the hearing threshold of the mice was measured using an auditory brainstem response (ABR) instrument. Subsequently, the mice were sacrificed and their cochlear tissues were collected for immunohistochemical staining. Figure 1B Kanamycin / furosemide-induced SNHL mice were shown, in which kanamycin (1 mg / g) and furosemide (0.1 mg / g) were injected subcutaneously (SC) or intraperitoneally (IP) on the first day, followed by IP6 (80 mg / kg), fucoxanthin (60 mg / kg) or their combination (80 mg / kg of IP6 and 30 mg / kg of fucoxanthin) intraperitoneally for 5 consecutive days. One week later, ABR hearing thresholds were measured and mouse cochlear tissues were collected. Figure 1C Mice with age-related hearing loss were shown, where IP6 (40 mg / kg or 80 mg / kg) was injected intraperitoneally 3 days a week for 10 months, or 2% IP6 was received through drinking water for 10 months. ABR hearing thresholds were measured every three months. When the experimental mice reached 12 months of age, the mice were sacrificed and their cochlear tissues were collected.

[0031] FIG. 2A to FIG. 2D Shown is the effect of IP6 injection on hair cell loss in cochlear tissue of cisplatin-injected mice. FIG. 2A to FIG. 2C Representative results of immunohistochemical staining, showing the top area of ​​the cochlear tissue in each group of mice ( Figure 2A ), Central Region( Figure 2B ) and bottom area ( Figure 2C ) nuclei (stained with DAPI, blue), hair cells (HC, stained with Myo7A, red) and cytoskeleton (stained with phalloidin, green) of the cochlear tissue. Scale bar = 25 μm. Arrows indicate the loss of outer hair cells (OHC) in cochlear tissue. Figure 2D show FIG. 2A to FIG. 2C Quantification of hair cell loss in mice. Cis: mice treated with cisplatin (3 mg / kg / day, IP). Cis+IP6: mice treated with cisplatin (3 mg / kg / day, IP) and IP6 (80 mg / kg / day, IP).

[0032] Figure 3A and Figure 3BShown is the effect of IP6 injection (40 mg / kg or 80 mg / kg) on ​​the hearing threshold of cisplatin-injected mice. Figure 3A Representative results of auditory brainstem responses (ABR) of mice in each group to a frequency of 12 kHz are shown. Figure 3B The average hearing threshold of each group of mice is shown. Cis: mice treated with cisplatin (3 mg / kg / day, IP). Cis+IP6 40: mice treated with cisplatin (3 mg / kg / day, IP) and IP6 (40 mg / kg / day, IP). Cis+IP6 80: mice treated with cisplatin (3 mg / kg / day, IP) and IP6 (80 mg / kg / day, IP).

[0033] 4A to 4D The effects of IP6, fucoxanthin or their combination on the hearing threshold of mice injected with kana / furosemide are shown. Figure 4A Representative results of auditory brainstem responses (ABR) of mice in each group to a frequency of 12 kHz are shown. Figure 4B and Figure 4C The mean hearing thresholds of mice in each group are shown. Figure 4D Representative results of immunohistochemical staining, showing the nuclei (stained with DAPI, blue), hair cells (stained with Myo7A, red) and cytoskeleton (stained with phalloidin, green) in the apical, middle and basal regions of the cochlear tissue in each group of mice. Scale bar = 25 μm. The white box indicates the loss of outer hair cells (OHC) in the cochlear tissue. Kana+Furo: mice treated with kanamycin and furosemide. Kana+Furo+IP6 80: mice treated with kanamycin, furosemide and IP6 (80 mg / kg / day, IP). Kana+Furo+IP6 80+Fuco30: mice treated with kanamycin, furosemide, IP6 (80 mg / kg / day, IP) and fucoxanthin (30 mg / kg / day, IP). Kana+Furo+Fuco 60: mice treated with kanamycin, furosemide and fucoxanthin (60 mg / kg / day, IP).

[0034] FIG. 5A to FIG. 5E Neuropathology gene panel analysis showing the protective effect of IP6 against kana / furosemide (Furo)-induced hearing loss in mice. Figure 5A The gene scores of biological pathways in the mRNA expression profile of cochlear tissues of each group of mice are shown. Figure 5B The gene scores of microglia, endothelial cells and neurons in the cochlear tissue of each group of mice were shown to show significant changes in gene expression. Figure 5C Heat maps showing gene expression profiles of various biological pathways after normalization based on a control group. Figure 5D and Figure 5E The significant changes in gene expression in the gene score of vesicle transport, myelination, lipid metabolism, and carbohydrate metabolism in the cochlear tissue of each group of mice are shown. Kana+Furo: mice treated with kanamycin and furosemide. Kana+Furo+IP6: mice treated with kanamycin, furosemide, and IP6 (80 mg / kg / day, IP).

[0035] FIG. 6A to FIG. 6G Shown are the effects of IP6 injection (40 mg / kg or 80 mg / kg) or IP6 drinking solution on hearing thresholds in aged mice (6, 9, and 12 months of age). FIG. 6A to FIG. 6E The mean hearing thresholds of mice in each group were measured by auditory brainstem response (ABR) at 12 kHz, and Fig. 6F Representative results of ABR for 12 kHz frequency of mice in each group are shown when the mice were 12 months old. Figure 6G Representative results of immunohistochemical staining, showing the nuclei (stained with DAPI, blue), hair cells (stained with Myo7A, red) and cytoskeleton (stained with phalloidin, green) in the top, middle and bottom regions of the cochlear tissue in each group of mice. Scale bar = 25 μm. Arrows indicate the loss of inner hair cells (IHC) in the cochlear tissue. White boxes indicate the loss of outer hair cells (OHC) in the cochlear tissue. IP6 40: mice treated with IP6 (40 mg / kg / day, IP). IP6 80: mice treated with IP6 (80 mg / kg / day, IP). IP6 drinking water: mice treated with IP6 (2%, oral). DETAILED DESCRIPTION

[0036] This specification discloses some embodiments in detail so that a person skilled in the art can utilize the embodiments based on the present application. All steps or features of these embodiments are not fully discussed in detail because many steps or features will be obvious to a person skilled in the art based on the present application.

[0037] It should also be noted that, as used in this application, the singular forms "a", "an", and "the" include plural referents unless expressly and unequivocally limited to one referent. The term "or" can be used interchangeably with the term "and / or" unless the context clearly indicates otherwise.

[0038] As used herein, the term "about" generally means within 10%, 5%, 1% or 0.5% of a given value or range. Alternatively, the term "about" means within the acceptable standard error of the mean value as considered by a person of ordinary skill in the art. Unless otherwise expressly specified, all numerical ranges, quantities, values ​​and percentages disclosed herein, such as numerical ranges, quantities, values ​​and percentages for material quantities, durations, temperatures, operating conditions, quantitative ratios, etc., should be understood to be modified by the term "about" in all cases.

[0039] The present application provides a method for preventing or treating hearing loss in a subject in need thereof, such as chronic or acute hearing loss caused by chemotherapy or antibiotics. In some embodiments of the present application, the method comprises administering to the subject an effective amount of a composition, wherein the composition comprises at least one of phytate or a salt or a derivative thereof and fucoxanthin or a derivative thereof, and at least one of a pharmaceutically acceptable excipient thereof and a food excipient thereof.

[0040] As used herein, the terms "including" or "comprising" are used to refer to the compositions, methods and respective components thereof contained in the present application, which are still open to include unspecified elements.

[0041] As used herein, the term "treatment" (treat, treating or treatment) covers partial or complete prevention, improvement, alleviation and / or control of symptoms, disorders or states associated with a disease. The term "treatment" as used herein means the application or administration of one or more therapeutic agents or surgery to a subject with symptoms, disorders or states associated with a disease, with the purpose of achieving partial or complete alleviation, improvement, relief, postponement of onset, inhibition of progression, reduction of severity and / or reduction of incidence for one or more symptoms, disorders or states associated with the disease. The treatment may be administered to a subject who only exhibits early signs of such symptoms, disorders and / or states to reduce the risk of developing symptoms, disorders and / or states associated with the disease.

[0042] As used herein, the term "prevention" or "prevention" means preventive or avoidance measures for a disease or a symptom or state associated with a disease, including but not limited to the administration or administration of one or more active agents to a subject who has not yet been diagnosed with the disease or a symptom or state associated with the disease, but the subject may be susceptible to the disease or prone to the disease. The purpose of preventive or avoidance measures is to avoid, prevent or postpone the occurrence of the disease or a symptom or state associated with the disease.

[0043] As used herein, the terms "patient", "individual" and "subject" are used interchangeably. The term "subject" means a human or an animal. Examples of subjects include, but are not limited to, rodents, mice, monkeys, guinea pigs, dogs, cats, cows, sheep, pigs, horses, rabbits and humans. In some embodiments of the present application, the subject is a mammal, for example a primate, such as a human.

[0044] As used herein, the phrase "effective amount" means the amount of active ingredient (e.g., phytate, fucoxanthin, or a combination thereof) required to impart the desired effect (e.g., protection of hair cells) to the treated subject. As recognized by those of ordinary skill in the art, the effective dose will vary depending on the route of administration, the excipients used, the possibility of co-use with other therapies, and the condition to be treated.

[0045] As used herein, the term "administering" or "administration" means placing the active ingredient (e.g., phytate, fucoxanthin, or a combination thereof) in the subject's body by a method or route that allows the active ingredient (e.g., phytate, fucoxanthin, or a combination thereof) to at least partially reach the desired site to produce the desired effect. The active ingredients described herein can be administered by any appropriate route known in the art, including but not limited to oral or parenteral routes, including intraperitoneal, intravenous, intradermal, intramuscular, subcutaneous or transdermal routes.

[0046] In at least one embodiment of the present application, the composition can be administered to the subject 1 to 4 times a day, 1 to 7 times a week, or 1 to 10 times a month. In some embodiments, the frequency of administration of the composition to the subject is selected from the group consisting of once a month, twice a month, three times a month, four times a month, five times a month, six times a month, seven times a month, eight times a month, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, once every three days, twice every three days, three times every three days, once every two days, twice every two days, once a day, and twice a day.

[0047] The composition of the present application may include phytate or its salt or derivative thereof as the sole active ingredient for preventing or treating hearing loss. That is, phytate or its salt or derivative thereof is used as the sole active ingredient for hearing dysfunction in the composition. Alternatively, the composition of the present application may include fucoxanthin or its derivative as the sole active ingredient for preventing or treating hearing loss. That is, fucoxanthin or its derivative is used as the sole active ingredient for hearing dysfunction in the composition. In the embodiment, the present application provides a safe and effective therapy for preventing or treating hearing loss by using phytate or its salt or derivative thereof or fucoxanthin or its derivative alone as an active ingredient.

[0048] Alternatively, in other embodiments, the composition may include a combination of phytate or its salt or derivative and fucoxanthin or its derivative. In the embodiments, the combination has a synergistic effect in rescuing the loss of cochlear hair cells and lowering the hearing threshold, thereby safely and effectively preventing or treating hearing loss.

[0049] As used herein, the term "synergistic" means a combination of therapies that is more effective than the individual monotherapies.

[0050] Alternatively, in other embodiments, in addition to phytate or its salt or its derivative and fucoxanthin or its derivative, unless the effect of the present application is inhibited, the composition may be administered to the subject in combination with another active ingredient for hearing loss. In such embodiments, phytate or its salt or its derivative and / or fucoxanthin or its derivative may be provided together with another active ingredient in a single preparation or separately in separate preparations.

[0051] The composition of the present application may be a pharmaceutical composition including a pharmaceutically acceptable excipient or an edible composition including a food excipient.

[0052] As used herein, the term "pharmaceutically acceptable excipient" means a pharmaceutically acceptable material, composition or vehicle, such as disintegrants, binders, lubricants and surfactants, which does not abrogate the biological activity or properties of the active ingredient and is relatively non-toxic; that is, the material can be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any component of the composition.

[0053] As used herein, the term "food excipient" means an edible material that may not be biologically active itself but improves the absorption of nutrients and active ingredients into the body; for example, a food excipient may protect nutrients and active ingredients until they reach the site where they are intended to act.

[0054] In at least one embodiment of the present application, the edible composition provided herein may include a cereal rich in phytate or its salt or its derivative. Examples of cereals rich in phytate or its salt or its derivative include, but are not limited to, rice bran, germ rice, and buckwheat. For example, it is reported that the content of phytate in rice bran ranges from 0.22% to 2.22%. [1] Based on the analysis method disclosed by Lehrfeld [2] , it was found that 100 grams of germ rice extract can contain about 509 mg of phytate.

[0055] In at least one embodiment of the present application, the edible composition provided herein may include seaweed or an extract thereof rich in fucoxanthin or its derivatives.

[0056] The present application will be described using a variety of embodiments, which should not be construed as limiting the scope of the present application.

[0057] Example

[0058] Materials and Methods

[0059] The materials and methods used in Examples 1 to 3 are described in detail below. Materials used in this application but not specified herein are commercially available.

[0060] (1) Animal model

[0061] This animal experiment was approved by the Animal Care Committee of Mackay Medical College. C57BL / 6J female mice (8 weeks old) were purchased from BioLasco. All animals were fed and maintained according to the following animal experimental procedures.

[0062] A schematic scheme of the administration and timing of cisplatin and IP6 for mice with cisplatin-induced sensorineural hearing loss (SNHL) is presented in Figure 1A Specifically, cisplatin was dissolved in 0.1% dimethylsulfoxide (DMSO) and injected intraperitoneally (IP) to induce ototoxicity in mice, following the procedure described by Wu et al. [3] . Inositol hexaphosphate (IP6) was purchased from Sigma (USA), dissolved in ddH2O, and the intraperitoneal injection doses of experimental mice were 40 mg / kg and 80 mg / kg (100 μL of IP6). First, IP6 was injected intraperitoneally into mice, and cisplatin was injected 2 hours later; subsequently, the mice were treated with IP6 for 4 consecutive days. The control group mice received only phosphate-buffered saline (PBS, 100 μL). For serum biochemical markers, namely aspartate transaminase (AST), alanine aminotransferase (ALT), and total bilirubin, there were no differences between the control group mice, mice injected with cisplatin, and mice injected with cisplatin and IP6 (data not shown).

[0063] A schematic flow chart of the administration and timing of kanamycin, furosemide, IP6, and / or fucoxanthin for kanamycin-induced SNHL mice is presented in Figure 1BKanamycin (Sigma Aldrich, USA) was dissolved in PBS, and a single dose of Kanamycin (1 mg / g) and furosemide (0.1 mg / g, Sigma Aldrich, USA) was injected on day 1. Specifically, after subcutaneous (SC) injection of Kanamycin, furosemide was injected intraperitoneally within 30 minutes. One hour later, IP6 and / or fucoxanthin were injected intraperitoneally for 5 consecutive days.

[0064] For the mouse model of age-related hearing loss (ARHL), this study used female C57BL / 6J mice of the following ages: [4] The schematic flow chart of the ARHL mouse model is presented in Figure 1C . To acclimate to the environment, the animals were housed for at least 1 week before the start of the experiment. The animals were maintained at 20°C to 26°C and a 12-hour light / dark cycle with a humidity of 40% to 70%, and were allowed free access to normal food and water until the start of the experiment. IP6 was dissolved in ddH2O, and the intraperitoneal injection doses of the experimental mice were 40 mg / kg and 80 mg / kg. In addition, IP6 was dissolved in ddH2O to prepare IP6 solution (2%), and was administered to mice in the form of drinking water.

[0065] All mice were anesthetized when auditory brainstem responses (ABR) were measured. Cochlear tissues were collected for further immunohistochemistry and gene expression analysis.

[0066] (2) Overall dissection, conjugate microscopy, and outer hair cell (OHC) loss counting

[0067] The experimental mice were anesthetized and their cochlear tissue was isolated and dissected. For the whole dissection, follow the procedure detailed by Neal et al. [5]. Briefly, the cochlea was decalcified for 1 hour using a decalcification solution purchased from Apex Engineering (Aurora, IL, USA). The excess temporal bone around the cochlea was trimmed, the cochlea was bisected along the mid-axial plane, and then immersed in phosphate-buffered saline (PBS). A series of incisions through the modiolus separated the half-turns from each other. Each half-turn was then removed from the surrounding temporal bone, and the tectorial membrane was removed. The cochlear tissue was fixed with 4% paraformaldehyde. The tissue was reacted with a primary antibody against Myo7A (1:100, Santa Cruz, CA) and a primary antibody against phalloidin conjugated to Alexa 488 (1:200, Thermo Fisher Scientific) at 4°C overnight and at 4°C for 2 hours, respectively. The tissue was reacted with a secondary antibody against rhodamine goat anti-mouse (1:200, KPL) at room temperature for 2 hours. Cells were stained with 4',6-diamidino-2-phenylindole (DAPI, Sigma).

[0068] For counting of OHC loss, hair cells (HC) were counterstained with phalloidin, Myo7A, and DAPI. Images were captured using a conjugate spectral microscope (Leica SP8). Images of three randomly selected regions (300 μm in length) in the top, middle, and bottom of the cochlear loop were acquired using the same equipment and OHC loss was counted manually. Then, the average OHC loss was calculated for the top, middle, and bottom regions, respectively. [6] Fluorescence images were taken using a Leica SP8 confocal fluorescence microscope.

[0069] (3) Auditory brainstem response (ABR) measurement

[0070] The ABR of mice was measured to evaluate their hearing threshold. In brief, the scalp of anesthetized mice was measured using subcutaneous needle electrodes placed on the top of the head, below the left auricle (measured as a reference) and below the contralateral ear (base). Sound stimulation included clicks (duration of 100 milliseconds; 4kHz, 8kHz and 12kHz). ABR measurement equipment (BIOPAC system, the United States) designed specifically for animal experiments was used. During the measurement of the hearing threshold, acoustic stimulation was applied directly to the ear canal, with a stimulus intensity ranging from 100 decibels (dB) sound pressure level to a threshold 10dB sound pressure level, at intervals of 10dB near the threshold level. The ABR threshold was measured by detecting the presence of a V wave. All procedures for ABR measurement are based on previous reports.[7-11] Make modifications.

[0071] (4) NanoString gene expression analysis

[0072] Refer to the process described in previous studies [10,11] Total mRNA was extracted from mouse cochlear tissue. The expression profile of neuropathological genes was analyzed using the NanoString Mouse Neuropathology Panel (NanoString Technologies, Seattle, WA, USA), which contains genes involved in neural cell types and neuropathological processes. [12,13] All gene or pathway score analyses were performed according to the nCounter Advanced Analysis Software user manual and have been described in detail in previous studies. [10,11] Cold Spring Harbor Biotech was responsible for NanoString gene expression analysis and bioinformatics analysis.

[0073] (5) Statistical analysis

[0074] Data are presented as mean ± standard deviation (SD). One-way analysis of variance was used for multiple group comparisons. Statistical significance was defined as P < 0.05.

[0075] Example 1: Effect of IP6 on cisplatin-induced chronic OHC loss in mice

[0076] In this example, 8-week-old mice were randomly divided into 3 groups (6 to 9 mice in each group): a control group, which was given 100 μL of PBS once a day for 5 consecutive days; a cisplatin group (Cis), which was injected intraperitoneally with cisplatin (3 mg / kg) once a day for 5 consecutive days; and a Cis+IP6 group, which was injected with IP6 (80 mg / kg) and then injected with cisplatin (3 mg / kg) 2 hours later, once a day for 5 consecutive days. The mice were sacrificed one week later, and cochlear tissues were obtained for immunohistochemical staining and OHC counting.

[0077] like FIG. 2A to FIG. 2D As shown, OHC (Myo7A + ) loss results showed that mice injected with cisplatin had significant loss of OHC in the top, middle, and bottom regions compared to the control group. After cisplatin-injected mice were treated with IP6, OHC loss in the top, middle, and bottom regions was significantly reduced compared to mice injected with cisplatin but not treated with IP6. This result suggests that IP6 can effectively prevent cisplatin-induced OHC loss.

[0078] Example 2: Effect of IP6 on Chronic Cisplatin-Induced Hearing Loss in Mice

[0079] In this example, 8-week-old female mice were randomly divided into 4 groups (6 to 9 mice in each group): a control group, which was given 100 μL of PBS once a day for 5 consecutive days; a cisplatin group (Cis), which was injected intraperitoneally with cisplatin (3 mg / kg) once a day for 5 consecutive days; a Cis+IP6 40 group, which was injected with IP6 (40 mg / kg) and then injected with cisplatin (3 mg / kg) 2 hours later, once a day for 5 consecutive days; and a Cis+IP6 80 group, which was injected with IP6 (80 mg / kg) and then injected with cisplatin (3 mg / kg) 2 hours later, once a day for 5 consecutive days. One week later, the hearing thresholds of mice in all groups were measured using an auditory brainstem response (ABR) instrument.

[0080] Results are shown in Figure 3A and Figure 3B In the study, it was shown that the hearing threshold of mice injected with cisplatin was significantly higher than that of mice in the control group, and after IP6 treatment, the hearing threshold of mice injected with cisplatin was significantly reduced from 40 decibels (db) to about 20db to 30db. This shows that IP6 can effectively improve chronic hearing loss caused by cisplatin.

[0081] Example 3: Effects of IP6 and / or Fuco on Kana / Furo-induced Hearing Loss in Mice

[0082] In this example, 8-week-old female mice were randomly divided into 5 groups (6 to 9 mice in each group): (1) control group: administered with 100 μL of PBS once a day for 5 consecutive days; (2) kanamycin / furosemide group: injected with kanamycin at a dose of 1 mg / g and furosemide at a dose of 0.1 mg / g; (3) Kana+Furo+IP6 group: injected with IP6 (80 mg / kg) 1 hour after kanamycin / furosemide injection on day 1 and on the remaining 4 days; (4) Kana+Furo+IP6 80+Fuco30 group: injected with IP6 (80 mg / kg) and fucoxanthin (30 mg / kg) 1 hour after kanamycin / furosemide injection on day 1 and on the remaining 4 days; and (5) Kana+Furo+Fuco 60 group: injected with fucoxanthin (60 mg / kg) 1 hour after kanamycin / furosemide injection on day 1 and on the remaining 4 days. One week later, the hearing thresholds of mice in all groups were measured using an auditory brainstem response (ABR) instrument. After ABR measurement, the mice were sacrificed and cochlear tissues were obtained for immunohistochemical staining.

[0083] Results are shown in FIG. 4A to FIG. 4CIn the study, it was shown that mice injected with kanamycin / furosemide had significantly higher hearing thresholds than control mice, while 5 consecutive days of IP6 treatment (80 mg / kg) or fucoxanthin treatment (60 mg / kg) resulted in a significant decrease in the hearing threshold of mice. In addition, the combined administration of IP6 and fucoxanthin further showed a synergistic effect in lowering the hearing threshold.

[0084] in addition, Figure 4D OHC (Myo7A + ) loss, and showed that OHC in the top, middle and bottom regions of the cochlear tissue of mice injected with kanamycin / furosemide was significantly lost. In mice injected with kanamycin / furosemide, 80mg / kg IP6 treatment significantly reduced OHC loss in the top, middle and bottom regions of the cochlear tissue. This result shows that IP6 can effectively prevent OHC loss caused by kanamycin and furosemide and improve hearing loss.

[0085] Example 4: Neuropathological gene expression analysis shows dysregulation in cochlear tissue of mice treated with kanamycin / furosemide and IP6

[0086] To analyze the NanoString gene expression profiles, the NanoString neuropathology gene expression panel was used to analyze the relative RNA abundance of three representative cochlear samples of the mouse groups described in Example 3, namely the control group (n=3, the hearing thresholds of all three samples at 12kHz were 10dB, 20dB and 20dB, respectively), the kanamycin / furosemide group (n=3, the hearing thresholds of all three samples at 12kHz were 50dB, 50dB and 60dB, respectively), and the Kana+Furo+IP6 group (n=3, the hearing thresholds of all three samples at 12kHz were 30dB, 40dB and 40dB, respectively).

[0087] like Figure 5A As shown in Figure 2, in mice injected with kanamycin / furosemide, the transcriptional patterns of astrocytes, endothelial cells, microglia, and neurons were reversed by treatment with 80 mg / kg IP6. Figure 5BThe results showed that after IP6 treatment, the gene scoring of microglia showed that the mRNA levels of Amigo1, Atp6v1a and Ap3m2 were significantly upregulated (P<0.05). In addition, the gene scoring of endothelial cells showed that the mRNA levels of Nrxn1 (P<0.01) and Prkcb (P<0.05) were significantly upregulated. IP6 treatment also significantly upregulated many neuronal scoring genes, such as Plcb4, Cacna1a, Calb1, Hcn1, Cnr1, Arhgap44, Gria4, Scn1a, Grik2, Cntnap1, Shank2, Lrrc4, Rab3a, Nrxn1, Adora1, Pak1, Frmpd4, Scn2a1, Dagla and Atcay (P<0.01).

[0088] Compared with the gene scores of cochlear tissues from mice injected with kanamycin / furosemide, the directed global significance score indicated that IP6 treatment upregulated many processes of neurorepair, including vesicle trafficking, axonal and dendritic structure formation, neural connectivity, neurotransmitter release, neurotransmitter response and reuptake, neurotransmitter synthesis and storage, growth factor signaling, myelination, carbohydrate metabolism, and lipid metabolism ( Figure 5C ).

[0089] After IP6 treatment, the gene score related to vesicle transport showed that the mRNA levels of Cacna1a, Calb1, Gabrb2, Syt4, Cnr1, Gria4, Grik2, Rims1, Cacnb4, Stx1b, Shank2, Fgf14, Syt13, Rab3a, Ncam1, Nrxn1, Adora1, Nova1, Gabra1 and Rit2 were significantly upregulated (P<0.01). In addition, the gene score for myelination showed that the mRNA level of Cntnap1 (P<0.01) and the mRNA levels of Scn2a1 and Amigo1 (P<0.05) were significantly upregulated. IP6 treatment also upregulated the mRNA levels of Cers6, Dgkb, Dgke, B4galt6, and Pla2g4c involved in lipid metabolism (P<0.05), as well as the mRNA levels of Akt3, Slc1a1, and Slc1a2 involved in carbohydrate metabolism (P<0.05). Figure 5D and Figure 5E ).

[0090] Example 5: Effect of IP6 injection on hearing threshold of aged mice

[0091] In this example, 2-month-old female mice were randomly divided into 4 groups (6 to 9 mice per group): IP6 40 group, IP6 40 mg / kg was injected intraperitoneally 3 days a week for 10 months; IP6 80 group, IP6 80 mg / kg was injected intraperitoneally 3 days a week for 10 months; IP6 drinking group, 2% IP6 was added to drinking water for 10 months (total IP6 intake was about 15 g to 20 g per mouse); and control group, PBS was injected intraperitoneally 3 days a week for 10 months. ABR measurements were performed on mice at 6, 9, and 12 months of age.

[0092] Fig. 6A showed that hearing thresholds increased in aged mice, while FIG. 6B to FIG. 6F The results of ABR measurements showed that the hearing function of the 12-month-old IP6-drinking group mice was significantly improved at a frequency of 12 kHz compared to the control group. The hearing threshold of the IP6-drinking group mice was reduced by 30% (about 20 dB) compared to the control group mice that did not receive IP6 treatment.

[0093] In addition, if Figure 6G As shown, in 12-month-old C57BL / 6J mice, administration of IP6 (80 mg / kg) or 2% IP6 in drinking water for 10 months moderately reduced the number of OHC (Myo7A) in the top, middle, and bottom regions of the cochlea. + In the basal region of the cochlear tissue of 12-month-old C57BL / 6J mice, inner hair cells (IHC) (Myo7A + ) (indicated by the white arrow), while the administration of IP6 (80 mg / kg) or 2% IP6 in drinking water could moderately alleviate the loss of IHCs in the basal area of ​​the mouse cochlear tissue.

[0094] From the above, it can be seen that IP6, fucoxanthin or a combination thereof provided in the present application can improve HC loss and hearing threshold, and can therefore be used to rescue hearing loss caused by chemotherapy, antibiotics or aging, thereby improving the quality of life of patients with cancer or infection and the elderly.

[0095] It is obvious to a person skilled in the art that the basic idea can be implemented in many ways as technology advances. Therefore, the implementation is not limited to the above-described embodiments; on the contrary, it may be modified within the scope of the claims.

[0096] The embodiments described above can be used in any combination with each other. Several embodiments can be combined together to form another embodiment. The compounds, compositions or methods disclosed herein may include at least one embodiment described above. It should be understood that the above benefits and advantages may relate to one embodiment or may relate to several embodiments. The embodiments are not limited to solving any or all of the problems described, nor are they limited to having any or all of the benefits and advantages described.

[0097] References:

[0098] [1]Saad N., Esa N., Ithnin H., et al., Optimization of optimum condition for phytic acid extraction from rice bran. African Journal of Plant Science 2011; 5(3): 168-176.

[0099] [2] Lehrfeld, J., High-performance liquid chromatography analysis ofphytic acid on a pH-stable, macroporous polymer column. Cereal Chemistry 1989;66(6):510-515.

[0100] [3]Wu X., Li

[0101] [4]Dong Y., Guo CR, Chen D., et al., Association between age-related hearing loss and cognitive decline in C57BL / 6Jmice. Molecular Medicine Reports2018;18:1726-1732.

[0102] [5]Neal C.,Kennon-McGill S.,Freemyer A.,et al.,Hair cell counts in arat model of sound damage:Effects of tissue preparation&identification ofregions of hair cell loss.Hearing Research 2015;328:120-132.

[0103] [6]Ninoyu Y.,Sakaguchi H.,Lin C.,et al.,The integrity of cochlearhair cells is established and maintained through thelocalization of Dia1 atapical junctional complexes andstereocilia.Cell Death and Disease 2020;11:536.

[0104] [7]Akil O.,Oursler A.E.,Fan K.,et al.,Mouse auditorybrainstemresponse testing.Bio-protocol 2016;6:e1768.

[0105] [8]Ingham N.J.,Pearson S.,Steel K.P.,Using the auditorybrainstemresponse(ABR)to determine sensitivity of hearingin mutant mice.CurrentProtocols in Mouse Biology 2011;1:279-287.

[0106] [9]Choi M.Y.,Yeo S.W.,Park K.H.,Hearing restoration in adeaf animalmodel with intravenous transplantation ofmesenchymal stem cells derived fromhuman umbilical cord blood.Biochemical and Biophysical ResearchCommunications 2012;427:629-636.

[0107]

[10] Tsai S.C.,Lin F.C.,Chang K.H.,et al.,Theintravenousadministration of skin-derived mesenchymal stem cellsameliorateshearing loss and preserves cochlear hair cells incisplatin-injected mice:SMSCs ameliorate hearing loss andpreserve outer hair cells in mice.HearingResearch.2022;413:108254.

[0108]

[11] Tsai S.C.,Yang K.D.,Chang K.H.,et al.,Umbilical cordmesenchymalstromal cell-derived exosomes rescue the loss ofouter hair cells and repaircochlear damage in cisplatin-injected mice.International Journal of MolecularSciences.2021;22(13):6664.

[0109]

[12] Rubino S.J.,Mayo L.,Wimmer I.,et al.,Acute microgliaablationinduces neurodegeneration in the somatosensory system.NatureCommunications.2018;9(1):4578.

[0110]

[13] Spangenberg E.,Severson P.L.,Hohsfield L.A.,et al.Sustainedmicroglial depletion with CSF1R inhibitor impairsparenchymal plaquedevelopment in an Alzheimer’s diseasemodel.Nature Communications.2019;10(1):3758.

Claims

1. A method for preventing or treating hearing loss in a subject in need thereof, comprising administering to the subject an effective amount of a composition, wherein: The composition comprises at least one of phytate or its salt or its derivative and fucoxanthin or its derivative, and at least one of its pharmaceutically acceptable excipient and its food excipient.

2. The method of claim 1, wherein: The hearing loss is congenital or acquired.

3. The method of claim 1, wherein: The hearing loss is caused by at least one of infection, noise exposure, chemotherapy, antibiotics and aging.

4. The method of claim 1, wherein: The subject suffers from hearing loss involving degeneration or loss of hair cells.

5. The method of claim 4, wherein: The hair cells are vestibular hair cells, cochlear hair cells or a combination thereof.

6. The method of claim 1, wherein: The subject suffers from at least one of sensorineural hearing loss, tinnitus, and vertigo.

7. The method of claim 1, wherein: The subject suffers from acute hearing loss, chronic hearing loss, primary tinnitus, Meniere's disease or labyrinthine concussion.

8. The method of claim 1, wherein: The salt or derivative of phytate is selected from the group consisting of sodium phytate, potassium phytate, calcium phytate, dipotassium phytate, calcium magnesium phytate, magnesium phytate and sodium phytate dodecahydrate.

9. The method of claim 1, wherein: The composition comprises the phytic acid or its salt or its derivative and does not contain the fucoxanthin or its derivative, and the phytic acid or its salt or its derivative is the only active ingredient in the composition for preventing or treating hearing loss.

10. The method of claim 1, wherein: The composition comprises the fucoxanthin or its derivative and does not contain the phytic acid or its salt or its derivative, and the fucoxanthin or its derivative is the only active ingredient in the composition for preventing or treating hearing loss.

11. The method of claim 1, wherein: The composition comprises the phytic acid or its salt or its derivative and the fucoxanthin or its derivative.

12. The method of claim 1, wherein: The phytic acid or its salt or derivative thereof or the fucoxanthin or its derivative thereof is present in an amount of 0.1% to 60% by weight of the composition.

13. The method of claim 1, wherein: The phytic acid or its salt or derivative thereof or the fucoxanthin or its derivative thereof is administered to the subject in an effective amount of about 1 mg / kg / day to about 500 mg / kg / day.

14. The method of claim 13, wherein: The phytic acid or salt thereof or derivative thereof or the fucoxanthin or derivative thereof is administered to the subject in an effective amount of about 3 mg / kg / day to about 80 mg / kg / day.

15. The method of claim 1, wherein: The composition is administered to the subject orally, intravenously, subcutaneously, intradermally, intrathecally, intraperitoneally, intranasally, intramuscularly, intrapleurally, topically, or by aerosolization.

16. The method of claim 1, wherein: The composition is a pharmaceutical composition or an edible composition.

17. The method of claim 16, wherein: The edible composition includes at least one of soybean, barley, corn, millet, rice bran, germ rice, wheat, buckwheat, husked grains, roasted husked grains, oak, quinoa seeds, seaweed and extracts thereof.

18. The method of claim 1, wherein: The composition is in a form selected from the group consisting of injection, dry powder, lozenge, oral solution, tablet, film, buccal lozenge, capsule, granule, pill, gel, lotion, ointment, emulsion, paste, cream, eye drops and salves.

19. The method of claim 1, wherein: The pharmaceutically acceptable excipient or the food excipient is selected from the group consisting of fillers, binders, preservatives, disintegrants, lubricants, suspending agents, wetting agents, solvents, surfactants, acids, flavoring agents, polyethylene glycol, alkyl glycol, sebacic acid, dimethyl sulfoxide, alcohols, calcium stearate, microcrystalline cellulose, silicon dioxide, gelatin, fat, glycerol, dietary fiber, alginate, pectin, carrageenan, amidated pectin, xanthan gum, gellan gum, karaya gum, rhamnose gum, welan gum, gum arabic, and any combination thereof.

20. The method of claim 1, wherein: The frequency of administration of the composition to the subject is selected from the group consisting of once a month, twice a month, three times a month, four times a month, five times a month, six times a month, seven times a month, eight times a month, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, once every three days, twice every three days, three times every three days, once every two days, twice every two days, once a day, and twice a day.